Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Rozlytrek
Rozlytrek
NICE backs funding for Roche’s lung cancer drug after price cut
Pharmaforum
Mon, 06/15/20 - 10:21 am
NICE
Roche
Rozlytrek
non-small cell lung cancer
Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi
Reuters
Sat, 08/17/19 - 12:08 am
Roche
Rozlytrek
Bayer
Eli Lilly
personalized medicine
Four New Drugs are Around the Corner. Here’s What You Need to Know.
Xconomy
Thu, 08/15/19 - 11:39 pm
FDA
drug approvals
AbbVie
Upadacitinib
Exondys 51
Sarepta Therapeutics
Nabriva Therapeutics
lefamulin
Roche
Rozlytrek
Roche scores double cancer approval for new Bayer rival Rozlytrek
Fierce Pharma
Thu, 08/15/19 - 11:32 pm
Roche
Rozlytrek
FDA
NTRK fusion-positive tumors
non-small cell lung cancer
Look out, Bayer: Roche scores first global nod for targeted cancer drug Rozlytrek
Fierce Pharma
Tue, 06/18/19 - 10:30 am
Roche
Rozlytrek
Japan
cancer
Bayer Vitrakvi